Zacks Research Lifts Earnings Estimates for Avanos Medical

Avanos Medical, Inc. (NYSE:AVNS) – Stock analysts at Zacks Research lifted their Q3 2027 earnings estimates for Avanos Medical in a report issued on Tuesday, May 26th. Zacks Research analyst Team now anticipates that the company will earn $0.26 per share for the quarter, up from their prior forecast of $0.25. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for Avanos Medical’s current full-year earnings is $1.06 per share. Zacks Research also issued estimates for Avanos Medical’s FY2027 earnings at $0.94 EPS.

Avanos Medical (NYSE:AVNS) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $0.22 earnings per share for the quarter, topping analysts’ consensus estimates of $0.16 by $0.06. The business had revenue of $182.20 million during the quarter, compared to analyst estimates of $170.00 million. Avanos Medical had a negative net margin of 10.39% and a positive return on equity of 5.39%. The company’s revenue was up 8.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.26 earnings per share.

A number of other brokerages have also weighed in on AVNS. Weiss Ratings upgraded shares of Avanos Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, April 22nd. Wall Street Zen lowered shares of Avanos Medical from a “buy” rating to a “hold” rating in a research report on Saturday, April 18th. Two research analysts have rated the stock with a Sell rating, Based on data from MarketBeat.com, Avanos Medical presently has an average rating of “Sell”.

Avanos Medical Stock Performance

AVNS opened at $24.80 on Thursday. The firm has a market cap of $1.16 billion, a P/E ratio of -15.40 and a beta of 1.58. Avanos Medical has a 1-year low of $9.30 and a 1-year high of $24.91. The company has a 50 day simple moving average of $20.33 and a two-hundred day simple moving average of $15.33. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.48 and a quick ratio of 1.40.

Hedge Funds Weigh In On Avanos Medical

A number of hedge funds and other institutional investors have recently modified their holdings of AVNS. AQR Capital Management LLC boosted its position in shares of Avanos Medical by 46.4% during the first quarter. AQR Capital Management LLC now owns 192,864 shares of the company’s stock worth $2,700,000 after acquiring an additional 61,095 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Avanos Medical by 4.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,955 shares of the company’s stock valued at $386,000 after purchasing an additional 1,121 shares in the last quarter. Millennium Management LLC raised its stake in Avanos Medical by 508.3% during the first quarter. Millennium Management LLC now owns 547,740 shares of the company’s stock valued at $7,849,000 after purchasing an additional 457,703 shares in the last quarter. Empowered Funds LLC raised its stake in Avanos Medical by 5.4% during the first quarter. Empowered Funds LLC now owns 162,182 shares of the company’s stock valued at $2,324,000 after purchasing an additional 8,348 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Avanos Medical by 17.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 140,810 shares of the company’s stock valued at $2,018,000 after purchasing an additional 20,541 shares in the last quarter. Institutional investors own 95.17% of the company’s stock.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.